1 The EIC Accelerator Project
EIC Accelerator Program Overview
The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support innovative small and medium-sized enterprises (SMEs) and startups in Europe, particularly those engaged in deep technology and high-risk innovation. The program aims to provide funding and support to highly promising projects that have the potential to contribute significantly to the European economy and society.
The EIC Accelerator offers a blended financing model that includes grants and equity investments. Grants can go up to €2.5 million, intended to cover specific project costs such as research and development, prototyping, and testing. Additionally, the program provides equity funding, which can reach up to €15 million until 2024 and €10 million from 2025 onwards. This equity financing is crucial for startups seeking to scale their operations and market presence, as it allows them to leverage private sector investments alongside EIC support.
Purpose of the EIC Accelerator
The EIC Accelerator plays a vital role in the European deep tech and startup ecosystem by bridging the funding gap for innovative projects that traditional investors might overlook. The program not only offers financial support but also provides access to a network of business coaches, mentors, and potential partners. This support is essential for companies looking to commercialize their technologies, navigate regulatory challenges, and gain visibility in competitive markets.
By focusing on high-risk, high-reward innovations, the EIC Accelerator aims to foster a vibrant entrepreneurial culture within Europe. It encourages the development of groundbreaking technologies that have the potential to address societal challenges, such as healthcare, climate change, and sustainable development.
NEOGAP Therapeutics AB and the NEOpTTL Project
NEOGAP Therapeutics AB, a Swedish company, emerged as a winner of the EIC Accelerator program with its project NEOpTTL, an innovative approach to individualized T-cell immunotherapy for cancer. The project focuses on using Personalized Tumour Trained Lymphocytes (pTTL) to create a reliable, cost-effective, scalable, and easy-to-implement cancer treatment.
Technology Basics and Background
The NEOpTTL project aims to revolutionize cancer treatment by developing a personalized immunotherapy that harnesses the power of the body’s own immune system. Traditional cancer therapies often face challenges such as limited efficacy, severe side effects, and the risk of tumor recurrence. NEOGAP Therapeutics addresses these issues by employing a novel method that trains T-cells to specifically target and eliminate cancer cells.
The process involves isolating T-cells from a patient’s blood and exposing them to tumor antigens. This exposure trains the T-cells to recognize and attack the cancer cells effectively. The personalized aspect of this therapy ensures that each patient receives a treatment tailored to their specific tumor characteristics. This individualized approach not only enhances the effectiveness of the therapy but also minimizes adverse effects commonly associated with conventional treatments.
The pTTL technology is designed to be scalable and cost-effective, allowing for broader access to this advanced form of immunotherapy. By simplifying the implementation process, NEOGAP Therapeutics aims to make personalized cancer treatments available to a wider range of patients and healthcare providers.
Conclusion
The EIC Accelerator's support for NEOGAP Therapeutics and its NEOpTTL project exemplifies the program's commitment to fostering innovative solutions in the healthcare sector. By providing necessary funding and resources, the EIC Accelerator enables companies like NEOGAP to scale their operations and develop groundbreaking therapies that could significantly improve cancer treatment outcomes. The integration of personalized medicine with advanced immunotherapy represents a significant step forward in the ongoing battle against cancer, positioning Europe at the forefront of medical innovation.
2 The Funding Rounds
NEOGAP Therapeutics AB: Financing and Funding Overview Since EIC Accelerator Win
NEOGAP Therapeutics AB, a Swedish biotechnology company focused on personalized immunotherapy for cancer, has actively expanded its funding base and investor network since submitting its successful EIC Accelerator application in March 2023. Below is a detailed summary of the company’s financing events, funding rounds, investor involvement, and related exit or acquisition information since that date.
Financing Raised & Funding Rounds
- In November 2023, NEOGAP raised a total of SEK 83 million (approximately €7.2 million) for its ongoing clinical phase I/II study in colorectal cancer. This capital comprised:
- SEK 54 million (~€4.7 million) from a new share issue led by Sciety and Sciety Venture Partners.
- SEK 29 million (~€2.5 million) in non-dilutive innovation grant funding from the European Innovation Council (EIC) Accelerator.
- In March 2024, NEOGAP secured an additional SEK 5 million (~€440k) grant through the Eurostars SME programme to support a collaborative project with French biotech Okomera.
Timing and Amounts of Major Rounds
| Date | Investor(s)/Programme | Amount Raised | Type |
|---|---|---|---|
| Nov 2023 | Sciety & Sciety Venture Partners | SEK 54m (€4.7m) | Equity (share issue) |
| Nov 2023 | EIC Accelerator | SEK 29m (€2.5m) | Grant |
| Mar 2024 | Eurostars SME Programme | SEK 5m (€440k) | Grant |
These rounds follow an earlier fundraising event: - February–March 2022: NEOGAP raised SEK 58 million to support early-stage clinical activities.
Investor Information
- The key private investors in recent rounds have been:
- Sciety, an investment company specializing in life sciences.
- Sciety Venture Partners, which co-invests alongside Sciety.
- Public sector/non-dilutive grants from European Innovation Council (EIC) and Eurostars SME Programme.
- Both Sciety firms first invested prior to this period but have continued their support as lead investors.
Company Valuations
Exit Events: IPOs, Buyouts, Acquisitions
- As of May 2025:
- There have been no reported IPOs or public market exits for NEOGAP Therapeutics AB.
- There is no record of buyouts by larger pharmaceutical companies or mergers with other entities.
- In June 2023, NEOGAP acquired the remaining shares (30%) in TCER Oncology AB—its subsidiary—broadening its patent portfolio but not constituting an external acquisition or exit event.
Summary Table: Key Funding Events Since March/April 2023
| Event/Date | Investors / Programmes | Amount |
|---|---|---|
| Share Issue Nov 2023 | Sciety & Sciety Venture Partners | SEK 54M |
| EU Grant Nov 2023 | EIC Accelerator | SEK 29M |
| R&D Grant Mar 2024 | Eurostars SME Programme | SEK 5M |
NEOGAP’s latest capital injections reinforce its position as an innovative leader advancing individualized cell therapies against solid tumors such as colorectal cancer while maintaining strong relationships with both private equity backers and European public grant agencies.
Sources
- Neogap raises SEK 83 million for a clinical phase I/II cancer study
- Sciety's portfolio company Neogap raises SEK 83 million
- NEOGAP Therapeutics — Dealroom Company Profile
- NEOGAP Therapeutics — InvestNY Profile
- News – Neogap.se
- Neogap secures Eurostars funding to develop T-cell activity analysis
3 The Press Releases
Neogap Therapeutics AB: A Swedish Biotechnology Company Advancing Personalised Immunotherapy
Neogap Therapeutics AB, based in Sweden, is a clinical-stage biotechnology company focused on developing personalised cancer immunotherapy. Since receiving the EIC Accelerator funding in March 2023, Neogap has made significant strides in advancing its innovative technologies and clinical trials.
Company Overview
Neogap Therapeutics is committed to providing hope for cancer patients through its pioneering cell therapy product, pTTL (personalised Tumour Trained Lymphocytes). This approach involves training the patient's own immune cells to target and eliminate cancer cells, offering a tailored treatment for each patient. The company leverages its proprietary PIOR® and EpiTCer® technologies to achieve this goal. PIOR® is a sophisticated software platform that uses DNA sequencing data and machine learning algorithms to identify tumour-specific mutations. EpiTCer® is a patented technology used to multiply T cells that can recognize and attack these selected targets.
Press Releases and Updates
Technology and Patents
- PIOR Technology: This software platform identifies tumour-specific mutations, crucial for developing personalised immunotherapies. A recent study using PIOR® identified potential neoantigens for liver cancer treatment.
- EpiTCer Technology: This patented technology is used to multiply T cells that target tumour-specific mutations identified by PIOR®. The European patent for EpiTCer® was granted in June 2023.
Future Outlook
Neogap Therapeutics continues to advance its personalised immunotherapy technologies, with ongoing clinical trials and strategic partnerships. The company's focus on innovation and precision cancer treatment positions it at the forefront of immuno-oncology research.
Sources
- News – NEOGAP
- NEOGAP Therapeutics AB - Cision News
- NEOGAP – Science for Cure
- Neogap secures EU patent for innovative personalised immunotherapy technology
- Neogap Therapeutics' PIOR technology identifies targets for personalised liver cancer immunotherapies
4 The Technology Advancements
NEOGAP Therapeutics AB: Current Capabilities and Advancements
Introduction to NEOGAP Therapeutics AB
NEOGAP Therapeutics AB is a Swedish clinical-stage biopharmaceutical company specializing in immuno-oncology, particularly in the development of personalized cancer immunotherapies. Founded in 2016 by Dr. Hans Grönlund, NEOGAP is located on the Karolinska hospital grounds in Solna, Sweden. The company's primary focus is on solid tumors, with an initial emphasis on colorectal cancer, using innovative technologies like PIOR and EpiTCer for personalized T-cell therapies.
Current Capabilities
NEOGAP's capabilities are centered around its proprietary technologies:
- PIOR: A software platform utilizing machine learning algorithms to identify optimal neoantigens for targeting in tumors.
- EpiTCer: A method for training T cells to target these identified neoantigens, enhancing the immune system's ability to attack cancer cells.
NEOGAP has also developed pTTL (Personalized Tumor Trained Lymphocytes), a cell therapy designed to treat solid tumors by leveraging the patient's immune system.
Advancements Since EIC Accelerator Funding
Since receiving funding from the European Innovation Council (EIC) Accelerator in March 2023, NEOGAP has made significant advancements:
- Strategic Partnership: NEOGAP partnered with NorthX Biologics, a leading contract development and manufacturing organization (CDMO), to advance the scalable manufacturing of its personalized cancer cell therapy. This collaboration is supported by ongoing EIC funding.
- Clinical Trials: NEOGAP successfully initiated a phase I/IIa clinical trial for its pTTL therapy in advanced colorectal cancer. The trial aims to assess the safety and tolerability of the treatment.
- Safety Data: Initial safety data from the trial have shown a positive safety profile, with no serious treatment-related adverse events observed.
Technological Improvements and New Features
NEOGAP's PIOR software has been instrumental in identifying tumor-specific mutations for personalized liver cancer immunotherapies, demonstrating the platform's versatility and potential for broader applications. Additionally, the company's collaboration with Simsen Diagnostics has showcased the integration of PIOR with Simsen Personal technology for more precise neoantigen identification and monitoring.
Market Demonstration
NEOGAP has not yet fully demonstrated its technology in the market with commercial products but has progressed significantly in clinical trials. The ongoing phase I/IIa trial for colorectal cancer represents a crucial step towards commercialization and patient access.
New Patents and Publications
While specific new patent filings or scientific studies published directly since the EIC funding are not detailed, NEOGAP's involvement in identifying targets for personalized liver cancer immunotherapies using its PIOR platform highlights ongoing research and development efforts.
Innovate Nordics 2025 Acceleration Program
NEOGAP was selected for the Innovate Nordics 2025 Acceleration Program, which supports Nordic companies entering the U.S. market. This recognition underscores NEOGAP's potential in the healthcare sector and its personalized cancer immunotherapy solutions.
Sources
- NEOGAP – Science for Cure
- Neogap Therapeutics selected for the Innovate Nordics 2025 Acceleration Program
- Neogap chosen for Innovate Nordics 2025 Acceleration Programme
- News – NEOGAP
- Neogap Therapeutics selected for Innovate Nordics 2025 Acceleration Program
- Neogap receives CTA approval for a phase I/IIa clinical trial with its advanced cell therapy
- Neogap receives Swedish agency approval for colorectal cancer
- Neogap Therapeutics selected for the Innovate Nordics 2025 Acceleration Program
- About - NEOGAP
5 The Partnerships and Customers
Since receiving the EIC Accelerator funding in March 2023, NEOGAP Therapeutics AB has been actively involved in several strategic partnerships to advance its innovative cancer therapies.Partnerships and Collaborations
New Partners and Customers
While specific new customer names are not mentioned, NEOGAP's involvement with NorthX Biologics and participation in the Innovate Nordics program indicates a growing network of partners and potential clients in the biotech and healthcare industries.
Nature of New Relationships
These partnerships are focused on enhancing NEOGAP's manufacturing capabilities and expanding its market reach. The collaboration with NorthX Biologics is technological in nature, aimed at scaling up NEOGAP's cell therapy production. The Innovate Nordics program provides business development opportunities and access to US markets, positioning NEOGAP for future growth.
Positioning in the Market
These relationships will help NEOGAP Therapeutics AB strengthen its presence in the global biotech market. By advancing its manufacturing capabilities and expanding into new markets, NEOGAP is well-positioned to increase its influence in the personalized cancer immunotherapy sector.
Technology Advancements and Scaling
The partnerships will significantly aid NEOGAP in technology advancements and scaling. The collaboration with NorthX Biologics enhances NEOGAP's ability to manufacture its cell therapies on a larger scale, which is essential for future clinical trials. The Innovate Nordics program will facilitate access to additional resources and networks that can support further technological innovations and commercialization strategies.
Sources
- Neogap Therapeutics News
- NEOGAP Therapeutics AB - Cision News
- NEOGAP – Science for Cure
- Neogap chosen for Innovate Nordics 2025 Acceleration Programme
- Neogap and NorthX Biologics Partner
6 The Hiring and Company Growth
NEOGAP Therapeutics AB: Team Growth and Strategic Expansion Post-EIC Accelerator Funding NEOGAP Therapeutics, a Swedish clinical-stage biopharmaceutical company specializing in personalized cancer immunotherapy, has demonstrated steady growth in its team and operations since securing funding. While specific headcount figures are not publicly disclosed, the company’s ongoing clinical trials, technology advancements, and participation in accelerator programs suggest strategic scaling efforts.- Team Structure: The company emphasizes its diverse team of professionals from academia and pharmaceutical industries, but exact team size remains unspecified. Recent leadership appointments include Dr. Hanjing Xie as Chief Medical Officer (CMO) in March 2023 to oversee clinical development.
- Hiring Activity: NEOGAP has not explicitly publicized current hiring campaigns but continues to expand through collaborations (e.g., with Simsen Diagnostics) and accelerator programs like Innovate Nordics 2025, which often correlate with operational scaling.
- Growth Trajectory: The completion of a SEK 58 million ($5.5M) funding round in early 2022 supported the initiation of its Phase I/IIa colorectal cancer trial, while recent grants (e.g., the $125K ScaleReady G-Rex Grant) indicate manufacturing scalability efforts.
- Key Hires: Dr. Xie’s appointment strengthened clinical oversight for their first-in-human trials, critical for advancing their pTTL therapy targeting neoantigens using proprietary PIOR® and EpiTCer® technologies.
- Management Stability: Founders remain active, with no reported changes to the founding team led by Dr. Hans Grönlund since its 2016 inception. COO Andrea Salmén recently represented NEOGAP at Innovate Nordics 2025, highlighting leadership continuity.
New team members bolster expertise in drug development and manufacturing optimization—key to advancing pTTL through late-stage trials and commercialization. Participation in Innovate Nordics accelerates market entry into the U.S., supported by expanded investor networks tailored for growth-stage biotech firms.
Sources
7 The Media Features and Publications
NEOGAP Therapeutics AB: Overview and Activities Since EIC Accelerator Funding
NEOGAP Therapeutics AB, a Swedish clinical-stage biotechnology company, has been actively involved in various media, scientific, and industry events since receiving the EIC Accelerator funding in March 2023. Here is a comprehensive overview of the company's activities and media presence.
Media Features and Publications
NEOGAP Therapeutics has been featured in several press releases and media outlets, particularly highlighting advancements in its personalized immunotherapy for cancer treatment. Key publications include announcements about the company's safety data from clinical trials, grants received for innovative cancer treatments, and patent approvals for autoimmune disease treatments.
Content from Publications
Recent publications have focused on NEOGAP Therapeutics' personalized T-cell therapy, pTTL, which is currently in clinical trials for advanced colorectal cancer. These publications emphasize the safety profile of the treatment and its potential as a groundbreaking approach in immuno-oncology.
Podcasts or Interviews
There is no specific mention of NEOGAP Therapeutics' participation in podcasts or interviews. However, the company's participation in conferences often involves presentations and discussions by key team members, such as Guro Gafvelin, the Chief Technology Officer.
Conference and Fair Visits
NEOGAP Therapeutics has participated in several conferences and events:
- Swiss Nordic Bio 2025: The company attended this event in Zurich, Switzerland, focusing on biotech and pharmaceutical networking opportunities.
- Biologics World Nordics 2025: Guro Gafvelin presented on personalized T-cell therapies for cancer in Stockholm, Sweden.
- ATMP Sweden 2024: NEOGAP showcased its developments in personalized tumor-trained lymphocytes at this conference in Malmö, Sweden.
- SITC 2024: The company presented a poster on its neoantigen-targeted T-cell therapy for colorectal cancer at the Society for Immunotherapy of Cancer (SITC) Conference in Houston, USA.
Involvement in Events
NEOGAP Therapeutics is actively involved in industry events, aiming to advance personalized immunotherapy. This includes collaborations with hospitals and research institutions for clinical trials.
Recent Developments
In April 2025, NEOGAP Therapeutics was selected for the prestigious Innovate Nordics 2025 Acceleration Program, further solidifying its position in the biotech industry. Additionally, the company received initial positive safety data from its phase I/II trial, reinforcing confidence in its personalized immunotherapy.
Sources
- News – NEOGAP
- NEOGAP – Science for Cure
- NEOGAP Therapeutics AB - Cision News
- Neogap Therapeutics selected for the Innovate Nordics 2025
- Who is NEOGAP?
- First patients treated in Neogap Therapeutics' personalised immunotherapy trial
- Events - NEOGAP
- Initial data from Neogap Therapeutics' personalised immunotherapy trial supports a positive safety profile
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.